PMID- 37113185
OWN - NLM
STAT- MEDLINE
DCOM- 20230501
LR  - 20230501
IS  - 2296-2565 (Electronic)
IS  - 2296-2565 (Linking)
VI  - 11
DP  - 2023
TI  - Investigation of treatment satisfaction and health-related quality of life after 
      add-on to metformin-based therapy in patients with type 2 diabetes.
PG  - 1152284
LID - 10.3389/fpubh.2023.1152284 [doi]
LID - 1152284
AB  - BACKGROUND: The complexity of oral antidiabetic drug (OAD) regimens affects the 
      quality of life (QOL) and treatment satisfaction. However, data on the QOL of 
      patients with type 2 diabetes mellitus (T2DM) receiving metformin-based OAD 
      treatment in Asia are limited. Therefore, this study aimed to evaluate the QOL 
      and treatment satisfaction and explore the influencing factors and their 
      correlations among patients with T2DM receiving metformin-based OADs. METHODS: 
      This was a cross-sectional study conducted at the Outpatient Department of 
      Metabolism and Endocrinology at a medical center in Taiwan. Data were collected 
      using the Audit of Diabetes-Dependent Quality of Life (ADDQoL) and the Chinese 
      version of the Satisfaction with Oral Anti-Diabetic Agent Scale (C-SOADAS) 
      questionnaires from patients with T2DM using metformin. The outcomes were 
      analyzed by group and stratified based on the use of two, three, and more than 
      three OADs. The level of agreement between the questionnaires was analyzed using 
      Spearman's rank correlation coefficient. RESULTS: A total of 153 patients with 
      T2DM using metformin were included in this study. The average weighted impact 
      score in the ADDQoL was -2.11, with no significant differences between the three 
      groups. The C-SOADAS score showed a significant difference between the groups 
      using two, three, and more than three OADs (21.42 [1.98] vs. 20.43 [2.09] vs. 
      19.00 [2.24], p < 0.0001). The ADDQoL and C-SOADAS scores showed low correlations 
      between patients' QOL and treatment satisfaction. However, the impact of diabetes 
      on specific aspects of life was negatively correlated with the total C-SOADAS 
      scores. CONCLUSION: In Taiwan, a significantly greater effect on QOL was observed 
      among patients with fewer OAD classes and higher treatment satisfaction. This 
      study provides local evidence from self-reporting outcomes of patients with T2DM. 
      Further studies focusing on different populations and treatment regimens for QOL 
      are needed.
CI  - Copyright (c) 2023 Chang, Shen and Chen.
FAU - Chang, Yu-Wen
AU  - Chang YW
AD  - School of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan.
AD  - Department of Pharmacy, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, 
      Taiwan.
FAU - Shen, Feng-Chin
AU  - Shen FC
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
AD  - College of Medicine, Chang Gung University, Taoyuan, Taiwan.
FAU - Chen, Chung-Yu
AU  - Chen CY
AD  - School of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan.
AD  - Department of Pharmacy, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
AD  - Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung, 
      Taiwan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230411
PL  - Switzerland
TA  - Front Public Health
JT  - Frontiers in public health
JID - 101616579
RN  - 9100L32L2N (Metformin)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - *Metformin/therapeutic use
MH  - Quality of Life
MH  - Cross-Sectional Studies
MH  - Patient Satisfaction
MH  - Hypoglycemic Agents/therapeutic use
PMC - PMC10126269
OTO - NOTNLM
OT  - ADDQoL
OT  - C-SOADAS
OT  - quality of life
OT  - treatment satisfaction
OT  - type 2 diabetes
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/04/28 06:42
MHDA- 2023/05/01 06:42
PMCR- 2023/04/11
CRDT- 2023/04/28 02:24
PHST- 2023/01/27 00:00 [received]
PHST- 2023/03/15 00:00 [accepted]
PHST- 2023/05/01 06:42 [medline]
PHST- 2023/04/28 06:42 [pubmed]
PHST- 2023/04/28 02:24 [entrez]
PHST- 2023/04/11 00:00 [pmc-release]
AID - 10.3389/fpubh.2023.1152284 [doi]
PST - epublish
SO  - Front Public Health. 2023 Apr 11;11:1152284. doi: 10.3389/fpubh.2023.1152284. 
      eCollection 2023.